Incidence and management of edema associated with trebananib (AMG 386)

Gynecol Oncol. 2013 Sep;130(3):636-41. doi: 10.1016/j.ygyno.2013.05.023. Epub 2013 May 23.

Authors

Bradley J Monk¹, Lindsey Minion, Sandrina Lambrechts, Ignace B Vergote, Nele Devoogdt, Beth Y Karlan

Affiliation

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arizona Cancer Center, Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA. Bradley.monk@chw.edu

PMID: 23707665
DOI: 10.1016/j.ygyno.2013.05.023

No abstract available

Keywords: AMG 386; Anti-angiogenic agent; Edema; Ovarian cancer; Trebananib.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / adverse effects*
Carcinoma, Ovarian Epithelial
Edema / chemically induced*
Edema / therapy*
Female
Humans
Neoplasms, Glandular and Epithelial / drug therapy*
Ovarian Neoplasms / drug therapy*
Recombinant Fusion Proteins / adverse effects*

Substances

Angiogenesis Inhibitors
Recombinant Fusion Proteins
trebananib